YERVOY
Biological
E.R. Squibb & Sons, L.L.C.
Total Payments
$6.7M
Transactions
547
Doctors
213
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $229,725 | 3 | 1 |
| 2023 | $438,186 | 16 | 10 |
| 2022 | $505,431 | 53 | 32 |
| 2021 | $326,035 | 48 | 30 |
| 2020 | $440,636 | 53 | 31 |
| 2019 | $889,782 | 52 | 29 |
| 2018 | $1.2M | 113 | 16 |
| 2017 | $2.6M | 209 | 91 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $6.6M | 242 | 98.6% |
| Consulting Fee | $75,488 | 42 | 1.1% |
| Travel and Lodging | $11,052 | 12 | 0.2% |
| Food and Beverage | $3,662 | 246 | 0.1% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $745.00 | 1 | 0.0% |
| Education | $22.48 | 4 | 0.0% |
Payments by Type
Research
$6.6M
242 transactions
General
$90,969
305 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| GMA ECOG Phase III ECOG1609 Adjuvant melanoma | E.R. Squibb & Sons, L.L.C. | $1.0M | 0 |
| 2016 Y 0076 IntraTumor IO in vivo screening platform | E.R. Squibb & Sons, L.L.C. | $539,706 | 0 |
| Phase II Study of Nivolumab plus Ipilimumab for Uveal Melanoma | E.R. Squibb & Sons, L.L.C. | $437,134 | 0 |
| Ph III STY OF ADJ IPI ANTI-CTLA4 THERAPY Vs HIGH-DOSE INTERFERON a-2b FOR RESECTED HIGH-RISK MEL | E.R. Squibb & Sons, L.L.C. | $429,574 | 0 |
| Quantifying the Immune Cell Targets of CTLA4 and PD1 Therapy in Melanoma | E.R. Squibb & Sons, L.L.C. | $423,274 | 0 |
| A Phase I Ib Study of Ipilimumab in Patients with Relapsed H | E.R. Squibb & Sons, L.L.C. | $396,887 | 0 |
| Pathology of Durable Stable Disease in Melanoma Patients Treated with Ipilimumab | E.R. Squibb & Sons, L.L.C. | $321,753 | 0 |
| Ipilimumab and Osimertinib for Metastatic EGFR NSCLC | E.R. Squibb & Sons, L.L.C. | $307,846 | 0 |
| A phase II multi-cohort trial of ipilimumab with and without nivolumab in patients with relapsed/refractory classic Hodgkin lymphoma | E.R. Squibb & Sons, L.L.C. | $247,464 | 0 |
| A Phase II Study of Nivolumab + Ipilimumab + Cabozantinib in Patients with Brain Metastases from Renal Cell Carcinoma | E.R. Squibb & Sons, L.L.C. | $218,671 | 0 |
| Quantitative Analysis of the CTLA-4 Signaling Network in treatment experienced mCRPC samples | E.R. Squibb & Sons, L.L.C. | $200,000 | 0 |
| PhIII Adjuvant Melanoma EORTC | E.R. Squibb & Sons, L.L.C. | $193,503 | 0 |
| Randomized Multicenter Double Blind Phase 3 Trial Comparing the Efficacy of Ipilimumab Plus Etoposide Platinum Versus Etoposide Platinum in Subjects With Newly Diagnosed Extensive Stage Disease Small Cell Lung Cancer ED SCLC | E.R. Squibb & Sons, L.L.C. | $172,081 | 0 |
| 2016-Y-0076 IntraTumor IO in vivo screening platform | E.R. Squibb & Sons, L.L.C. | $140,613 | 0 |
| Ph I Sdy Ipi Comb W Whole Brain Radiation Therapy or Radiosurgery for Mel Pat W Brain Metastases | E.R. Squibb & Sons, L.L.C. | $135,367 | 0 |
| Phase IV PMR Dose Comparison 3 mg vs 10 mg | E.R. Squibb & Sons, L.L.C. | $127,078 | 0 |
| Phase IIA Yervoy BRAF Inhibitor sequence melanoma | E.R. Squibb & Sons, L.L.C. | $126,897 | 0 |
| Triplet combination therapy with ipilimumab, nivolumab, and cabozantinib in anti-PD-1 refractory metastatic cutaneous melanoma | E.R. Squibb & Sons, L.L.C. | $107,736 | 0 |
| Melanoma tumor exome sequencing RNASeq to explore potential mechanisms of resistance to ipilimumab | E.R. Squibb & Sons, L.L.C. | $98,946 | 0 |
| Ipilimumab plus lenalidomide after allogeneic and autologous stem cell transplantation for patients with lymphoid malignancies. | E.R. Squibb & Sons, L.L.C. | $97,875 | 0 |
Top Doctors Receiving Payments for YERVOY
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Columbus, OH | $6.6M | 238 |
| , M.D | Medical Oncology | Houston, TX | $12,113 | 11 |
| , M.D | Urology | Durham, NC | $6,300 | 2 |
| , MD | Hematology & Oncology | New York, NY | $5,893 | 10 |
| , MD | Internal Medicine | Baltimore, MD | $4,956 | 11 |
| , MD | Medical Oncology | New York, NY | $4,025 | 1 |
| Scott Tykodi | Medical Oncology | Seattle, WA | $3,500 | 1 |
| , MD | Internal Medicine | New York, NY | $3,450 | 1 |
| , M.D | Medical Oncology | Washington, DC | $3,450 | 1 |
| , MD | Surgery | Morristown, NJ | $3,300 | 1 |
| , M.D, PHD | Medical Oncology | Houston, TX | $3,300 | 1 |
| , M.D | Hematology & Oncology | Santa Monica, CA | $3,300 | 1 |
| , M.D | Anatomic Pathology & Clinical Pathology | Baltimore, MD | $3,120 | 5 |
| Komal Jhaveri | Internal Medicine | New York, NY | $2,875 | 1 |
| , MD | Medical Oncology | New York, NY | $2,875 | 1 |
| , M.D | Medical Oncology | New York, NY | $2,875 | 1 |
| , M.D | Surgical Oncology | New York, NY | $2,875 | 1 |
| , MD | Hematology & Oncology | Jacksonville, FL | $2,850 | 1 |
| , M.D | Medical Oncology | New York, NY | $2,375 | 1 |
| Jeffrey Weber | — | New York, NY | $2,049 | 2 |
| , MD | Hematology & Oncology | Lawrenceville, GA | $1,620 | 3 |
| , MD | Hematology & Oncology | Park Ridge, IL | $1,575 | 1 |
| , D.O | Hematology & Oncology | Cheverly, MD | $1,500 | 1 |
| , M.D.,PH.D | Specialist | New York, NY | $1,485 | 3 |
| , MD | Hematology & Oncology | Tucson, AZ | $1,350 | 2 |
Ad
Manufacturing Companies
Product Information
- Type Biological
- Total Payments $6.7M
- Total Doctors 213
- Transactions 547
About YERVOY
YERVOY is a biological associated with $6.7M in payments to 213 healthcare providers, recorded across 547 transactions in the CMS Open Payments database. The primary manufacturer is E.R. Squibb & Sons, L.L.C..
Payment data is available from 2017 to 2024. In 2024, $229,725 was paid across 3 transactions to 1 doctors.
The most common payment nature for YERVOY is "Unspecified" ($6.6M, 98.6% of total).
YERVOY is associated with 20 research studies, including "GMA ECOG Phase III ECOG1609 Adjuvant melanoma" ($1.0M).